Clinical trial • Phase I • Musculoskeletal | Immunology | Dermatology
JJP-1212 for Rheumatoid arthritis | Linear IgA bullous dermatosis
Phase I trial of JJP-1212 for Rheumatoid arthritis | Linear IgA bullous dermatosis. 76 participants.
Overview
- Trial Therapeutic Area
- Musculoskeletal | Immunology | Dermatology
- Trial Disease
- Rheumatoid arthritis | Linear IgA bullous dermatosis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-02-2024
- First CTIS Authorization Date
- 27-05-2024
Trial design
Phase I trial in Poland, Bulgaria.
- Target Sample Size
- 76
Recruitment
- Planned Sample Size
- 76
- Recruitment Window Months
- 42
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 76
Poland
- Earliest CTIS Part Ii Submission Date
- 25-04-2024
- Latest Decision Or Authorization Date
- 13-03-2026
- Processing Time Days
- 687
- Number Of Sites
- 1
- Number Of Participants
- 72
Sites
- Site Name
- Mtz Clinical Research Powered By Pratia
- Department Name
- Phase I unit
- Contact Person Name
- Małgorzata Zajda
- Contact Person Email
- badacz@pratia.com
Bulgaria
- Earliest CTIS Part Ii Submission Date
- 06-10-2025
- Latest Decision Or Authorization Date
- 23-03-2026
- Processing Time Days
- 168
- Number Of Sites
- 1
- Number Of Participants
- 4
Sites
- Site Name
- Alexandrovska University Hospital
- Department Name
- Department of Dermatology and Venereology
- Contact Person Name
- Kossara Drenovska
- Contact Person Email
- kosara.drenovska@gmail.com
Sponsor
Primary sponsor
- Full Name
- Jjp Biologics Sp. z o.o.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Poland
Investigational products
- Investigational Product Name
- JJP-1212